Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Filgrastim

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2028 · 611 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Filgrastim (ATC-Code nach WHO: L03AA02)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed minimum purchase; actual demand depends on prescribing behavior and patient numbers, making revenue highl...

The buyer may terminate the Open-House early if exclusive discount agreements are concluded, which historically occurs...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Filgrastim (ATC L03AA02) pharmaceutical products to AOK PLUS for insured persons in Saxony and Thuringia.
  • Non-exclusive discount agreements under §130a Abs. 8 SGB V.
Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Filgrastim (ATC L03AA02) under §130a Abs. 8 SGB V, using an Open-House model. The buyer is AOK PLUS for the regions of Saxony and Thuringia, Germany. The agreement runs until 30 April 2028, with continuous enrollment. No estimated value or award criteria are provided. The procedure is not a classic public procurement but a voluntary transparency measure. Key risks include no guaranteed volume, strict confidentiality, potential early termination if exclusive agreements are concluded, and the requirement to access procurement documents via a restricted portal.

Risques

No guaranteed minimum purchase; actual demand depends on prescribing behavior and patient numbers, making revenue highl...

The buyer may terminate the Open-House early if exclusive discount agreements are concluded, which historically occurs...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG.
  • Company seat must be in Germany, EU, or EEA.

Eligibility

  • No grounds for exclusion under §§123, 124 GWB.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Filgrastim

Open-House model for non-exclusive discount agreements on Filgrastim (ATC L03AA02). The agreement covers supply of pharmaceutical products for the regions of Saxony and Thuringia. No minimum volume is guaranteed. The contract ends 30 April 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 30, 2028

Détails de la procédure

Date de publication
25 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
135009-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30